DE
AVXL icon

Defiance ETFs’s Anavex Life Sciences AVXL Stock Holding History

Defiance ETFs’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Buy
+13,216
New +$39.1K ﹤0.01% 388

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Defiance ETFs's AVXL Position: Q2 2026 in Review

Defiance ETFs opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 13,216 shares worth $34.1K. The stake represents ﹤0.01% of the portfolio and ranks #388 among its holdings.

178 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Defiance ETFs held 13,216 shares of Anavex Life Sciences worth $34.1K as of Q2 2026.
  • Anavex Life Sciences was a new Defiance ETFs position in Q2 2026.
  • Anavex Life Sciences made up ﹤0.01% of Defiance ETFs's portfolio in Q2 2026, its #388 holding.
  • 178 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Defiance ETFs's 13F filing for Q2 2026, filed 14 Aug 2026.